Comparison 6.

Targeted immunotherapy alone versus standard targeted therapies in previously treated patients with metastatic renal cell carcinoma

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 1‐year mortality	1	821	Risk Ratio (M‐H, Random, 95% CI)	0.70 [0.56, 0.87]
2 Overall survival	1		Hazard Ratio (Random, 95% CI)	0.73 [0.60, 0.89]
3 Quality of life	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.1 Clinical important MID in FKSI‐DRS	1	704	Risk Ratio (M‐H, Random, 95% CI)	1.51 [1.28, 1.78]
3.2 Clinical important MID in EQ‐5D‐VAS	1	703	Risk Ratio (M‐H, Random, 95% CI)	1.37 [1.16, 1.61]
4 Adverse events (grade ≥ 3)	1	803	Risk Ratio (M‐H, Random, 95% CI)	0.51 [0.40, 0.65]
5 Progression‐free survival	1		Hazard Ratio (Random, 95% CI)	0.88 [0.75, 1.03]
6 Tumour remission	1	750	Risk Ratio (M‐H, Random, 95% CI)	4.39 [2.84, 6.80]